493 related articles for article (PubMed ID: 17536071)
1. Increased body iron stores of obese women with polycystic ovary syndrome are a consequence of insulin resistance and hyperinsulinism and are not a result of reduced menstrual losses.
Luque-Ramírez M; Alvarez-Blasco F; Botella-Carretero JI; Sanchón R; San Millán JL; Escobar-Morreale HF
Diabetes Care; 2007 Sep; 30(9):2309-13. PubMed ID: 17536071
[TBL] [Abstract][Full Text] [Related]
2. Serum uric acid concentration as non-classic cardiovascular risk factor in women with polycystic ovary syndrome: effect of treatment with ethinyl-estradiol plus cyproterone acetate versus metformin.
Luque-Ramírez M; Alvarez-Blasco F; Uriol Rivera MG; Escobar-Morreale HF
Hum Reprod; 2008 Jul; 23(7):1594-601. PubMed ID: 18375410
[TBL] [Abstract][Full Text] [Related]
3. Effects of metformin and ethinyl estradiol-cyproterone acetate on clinical, endocrine and metabolic factors in women with polycystic ovary syndrome.
Wu J; Zhu Y; Jiang Y; Cao Y
Gynecol Endocrinol; 2008 Jul; 24(7):392-8. PubMed ID: 18608522
[TBL] [Abstract][Full Text] [Related]
4. Antiandrogenic contraceptives increase serum adiponectin in obese polycystic ovary syndrome patients.
Luque-Ramírez M; Alvarez-Blasco F; Escobar-Morreale HF
Obesity (Silver Spring); 2009 Jan; 17(1):3-9. PubMed ID: 18997670
[TBL] [Abstract][Full Text] [Related]
5. Endocrine and metabolic effects of metformin versus ethinyl estradiol-cyproterone acetate in obese women with polycystic ovary syndrome: a randomized study.
Morin-Papunen LC; Vauhkonen I; Koivunen RM; Ruokonen A; Martikainen HK; Tapanainen JS
J Clin Endocrinol Metab; 2000 Sep; 85(9):3161-8. PubMed ID: 10999803
[TBL] [Abstract][Full Text] [Related]
6. Comparison of ethinyl-estradiol plus cyproterone acetate versus metformin effects on classic metabolic cardiovascular risk factors in women with the polycystic ovary syndrome.
Luque-Ramírez M; Alvarez-Blasco F; Botella-Carretero JI; Martínez-Bermejo E; Lasunción MA; Escobar-Morreale HF
J Clin Endocrinol Metab; 2007 Jul; 92(7):2453-61. PubMed ID: 17426085
[TBL] [Abstract][Full Text] [Related]
7. Metformin administration is more effective when non-obese patients with polycystic ovary syndrome show both hyperandrogenism and hyperinsulinemia.
Genazzani AD; Lanzoni C; Ricchieri F; Baraldi E; Casarosa E; Jasonni VM
Gynecol Endocrinol; 2007 Mar; 23(3):146-52. PubMed ID: 17454168
[TBL] [Abstract][Full Text] [Related]
8. Treatment of polycystic ovary syndrome (PCOS) with metformin ameliorates insulin resistance in parallel with the decrease of serum interleukin-6 concentrations.
Luque-Ramírez M; Escobar-Morreale HF
Horm Metab Res; 2010 Oct; 42(11):815-20. PubMed ID: 20730705
[TBL] [Abstract][Full Text] [Related]
9. Comparison of effects of 3 mg drospirenone plus 20 μg ethinyl estradiol alone or combined with metformin or cyproterone acetate on classic metabolic cardiovascular risk factors in nonobese women with polycystic ovary syndrome.
Fruzzetti F; Perini D; Lazzarini V; Parrini D; Gambacciani M; Genazzani AR
Fertil Steril; 2010 Oct; 94(5):1793-8. PubMed ID: 19931080
[TBL] [Abstract][Full Text] [Related]
10. Metformin versus ethinyl estradiol-cyproterone acetate in the treatment of nonobese women with polycystic ovary syndrome: a randomized study.
Morin-Papunen L; Vauhkonen I; Koivunen R; Ruokonen A; Martikainen H; Tapanainen JS
J Clin Endocrinol Metab; 2003 Jan; 88(1):148-56. PubMed ID: 12519844
[TBL] [Abstract][Full Text] [Related]
11. The impact of oral contraceptives and metformin on anti-Müllerian hormone serum levels in women with polycystic ovary syndrome and biochemical hyperandrogenemia.
Panidis D; Georgopoulos NA; Piouka A; Katsikis I; Saltamavros AD; Decavalas G; Diamanti-Kandarakis E
Gynecol Endocrinol; 2011 Aug; 27(8):587-92. PubMed ID: 20836726
[TBL] [Abstract][Full Text] [Related]
12. Metformin decreases the adipokine vaspin in overweight women with polycystic ovary syndrome concomitant with improvement in insulin sensitivity and a decrease in insulin resistance.
Tan BK; Heutling D; Chen J; Farhatullah S; Adya R; Keay SD; Kennedy CR; Lehnert H; Randeva HS
Diabetes; 2008 Jun; 57(6):1501-7. PubMed ID: 18375437
[TBL] [Abstract][Full Text] [Related]
13. Alteration of ghrelin-neuropeptide Y network in obese patients with polycystic ovary syndrome: role of hyperinsulinism.
Romualdi D; De Marinis L; Campagna G; Proto C; Lanzone A; Guido M
Clin Endocrinol (Oxf); 2008 Oct; 69(4):562-7. PubMed ID: 18248643
[TBL] [Abstract][Full Text] [Related]
14. Rosiglitazone and ethinyl estradiol/cyproterone acetate as single and combined treatment of overweight women with polycystic ovary syndrome and insulin resistance.
Lemay A; Dodin S; Turcot L; Déchêne F; Forest JC
Hum Reprod; 2006 Jan; 21(1):121-8. PubMed ID: 16199428
[TBL] [Abstract][Full Text] [Related]
15. [Metformin, an efficacious drug in the treatment of polycystic ovary syndrome].
Hahn S; Quadbeck B; Elsenbruch S; Gärtner R; Finke R; Mann K; Janssen OE
Dtsch Med Wochenschr; 2004 May; 129(19):1059-64. PubMed ID: 15136950
[TBL] [Abstract][Full Text] [Related]
16. Effect of orlistat or metformin in overweight and obese polycystic ovary syndrome patients with insulin resistance.
Song J; Ruan X; Gu M; Wang L; Wang H; Mueck AO
Gynecol Endocrinol; 2018 May; 34(5):413-417. PubMed ID: 29172796
[TBL] [Abstract][Full Text] [Related]
17. Combined use of metformin and ethinyl estradiol-cyproterone acetate in polycystic ovary syndrome.
Mitkov M; Pehlivanov B; Terzieva D
Eur J Obstet Gynecol Reprod Biol; 2005 Feb; 118(2):209-13. PubMed ID: 15653205
[TBL] [Abstract][Full Text] [Related]
18. Effects of metformin on clinical and biochemical parameters in polycystic ovary syndrome.
Kriplani A; Agarwal N
J Reprod Med; 2004 May; 49(5):361-7. PubMed ID: 15214709
[TBL] [Abstract][Full Text] [Related]
19. Role of decreased circulating hepcidin concentrations in the iron excess of women with the polycystic ovary syndrome.
Luque-Ramírez M; Álvarez-Blasco F; Alpañés M; Escobar-Morreale HF
J Clin Endocrinol Metab; 2011 Mar; 96(3):846-52. PubMed ID: 21209031
[TBL] [Abstract][Full Text] [Related]
20. Metformin administration modulates neurosteroids secretion in non-obese amenorrhoic patients with polycystic ovary syndrome.
Genazzani AD; Strucchi C; Luisi M; Casarosa E; Lanzoni C; Baraldi E; Ricchieri F; Mehmeti H; Genazzani AR
Gynecol Endocrinol; 2006 Jan; 22(1):36-43. PubMed ID: 16522532
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
